The clinical research team at the Robert and Carol Weissman Cancer Center is now able to cover nearly the entire gamut of lung cancer stages (with the exception of stage IA) with clinical trials.
We’re excited to be able to offer a range of clinical trial options to our patients. Without clinical research, advancement in cancer therapies would come to a halt. Lung cancer is the leading cause of cancer death and new treatments must be trialed to become available to the general population.
For patients who had surgery and are stage IB-IIIA, we can offer the MAGRIT vaccine trial. Recently however, we’ve acquired studies that may offer patients additional treatment options for their lung cancer diagnoses. The first of the trials is a phase three trial of drug therapies followed by a maintenance program. To qualify for the trial, patients must have stage IIIB or IV non-small cell lung cancer of non-squamous histology.
The second trial is a first-line treatment involving radiation. Patients will be randomized to receive standard dose radiation therapy or high-dose radiation therapy. They will also receive concurrent and consolidation chemotherapy. To qualify for this trial, patients must have newly diagnosed non-small cell lung cancer, stage IIIA or IIIB.
Last, but not least, is a second-line treatment trial for non-small cell lung cancer, stage IIB/IV, or recurrent (non-squamous).
Patients will be screened and must meet the eligibility criteria before being enrolled in a clinical trial. Patients will be closely monitored by the study staff throughout the entire process.
To find out about these clinical trials and others available at the Robert and Carol Weissman Cancer Center, please call the research department at (772) 223-5945, ext. 1669.
--Lindsay Mattino, RN, BA
Clinical Research Coordinator
Genetics Nurse Educator
No comments:
Post a Comment